Fig. 9: Improved treatment effect with c-Myc inhibitor combined with Doxorubicin (DOX). | npj Precision Oncology

Fig. 9: Improved treatment effect with c-Myc inhibitor combined with Doxorubicin (DOX).

From: XRCC2 driven homologous recombination subtypes and therapeutic targeting in lung adenocarcinoma metastasis

Fig. 9: Improved treatment effect with c-Myc inhibitor combined with Doxorubicin (DOX).

a Measurement and recording of growth curves in two groups of nude mice, illustrating changes in body weight between the control and experimental groups. b Lung metastasis comparison between the combined drug group, control group, and single drug group, observed after peeling off the lungs. c, d Observation of tumor nodules and metastases in the liver and spleen after peeling off these organs. e, f IHC analysis detecting changes in XRCC2 and Vimentin protein expression in the combined drug group compared to the control and single drug groups. g Evaluation of VIM expression after XRCC2 knockdown combined with Dox in A549 cells. h Assessment of VIM expression after XRCC2 overexpression combined with Dox in PC9 cells. ***p < 0.001. The error bars represent the SEM.

Back to article page